Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.



How to prescribe Triumeq?

Gå till Stäng Överst

Once-daily TRIUMEQ makes dosing and administration simple for your patients

TRIUMEQ (dolutegravir/abacavir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. 1

Dosing recommendation 1

Triumeq dosing recommendation

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient. Abacavir should not be used in patients known to carry the HLA-B*5701 allele. [1] Find out more on HLA-B*5701 screening here.

Convenient dosing 1,2

Convenient dosing of Triumeq

Contraindications 1

Hypersensitivity to dolutegravir, abacavir or lamivudine or to any of the excipients. Co-administration with dofetilide.


For further information, please see Triumeq prescribing information

This medicinal product is subject to additional monitoring.

*TRIUMEQ is a fixed-dose pill and should not be prescribed for patients requiring dose adjustments. Separate preparations of dolutegravir, abacavir, and lamivudine are available in cases where discontinuation or dose adjustment is required. 1
TRIUMEQ is not recommended for patients with integrase inhibitor resistance.* 1
TRIUMEQ is not recommended for co-administration with efavirenz, nevirapine, rifampicin, or tipranavir/ritonavir. 1

*See How to prescribe Tivicay? for recommended dolutegravir dosing in patients with resistance to the integrase class.


  1. TRIUMEQ (dolutegravir/abacavir/lamivudine) Summary of Product Characteristics, January 2017.
  2. Kandel CE, Walmsley S. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Design, Development and Therapy. 2015:9 3547-3555.

TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies

Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.